Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

Inclusion Criteria: * Advanced or locally advanced pancreatic cancer patients (can include new or recurrent diagnosis) referred to SOCCI-CSMC for chemotherapy that has progressed through or intolerant to gemcitabine based chemotherapy * Cachexia defined as greater than 5% unexplained weight loss within any 6 month period prior to screening visit OR as documented by the medical physician based on standard diagnosis of cachexia * Age ≥ 18 years * ECOG performance status 0-2 or Karnofsky PS \>60% * Patients must have normal organ and marrow function * Ability to understand and the willingness to sign a written informed consent * Negative pregnancy test for WOCBP * WOCBP and men must agree to use of adequate contraception Exclusion Criteria: * Patients who are currently receiving any other investigational agents * Patients who have received more than one chemotherapeutic regimen in metastatic setting * Patients with CNS metastases * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Patients with unresolved grade 3/4 adverse effects of prior therapy at time of enrollment * Subjects with history of hypersensitivity to compounds of similar chemical or biologic composition to Xilonix or Onivyde * Women who are pregnant or breastfeeding * Dementia or altered mental status that would prohibit the understanding or rendering of informed consent * Patients with known Dihydropyrimidine dehydrogenase deficiency (DPD deficiency) * Patients known to be UGT1A1\*28 allele homozygous * Patients who have had a live vaccine within 3 months of enrollment